Therapeutic compositions and methods of use

Details Therapeutic compositions and methods of use Therapeutic compositions and methods of use

2007-10-30

2007-10-30

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C514S557000

Reexamination Certificate

active

10395372

ABSTRACT:
Compounds and methods useful for chemopreventative treatment of diseases such as cancer, Alzheimer's disease, Parkinson's disease, inflammatory bowel diseases, and multiple sclerosis.

REFERENCES:
patent: 4395423 (1983-07-01), Neumann
patent: 5603958 (1997-02-01), Morein et al.
patent: 6485756 (2002-11-01), Aust et al.
John F. Woodley, Liposomes For Oral Administration Of Drugs, Critical Reviews In Therapeutic Drug Carrier System., 2(1) pp. 1-18 1985.
Honda et al., “Novel synthetic oleanane and ursane triterpenoids with various enone functionalities in ring a as inhibitors of nitric oxide production in mouse macrophages,”J. Med. Chem.,43:1866-1877, 2000.
Honda et al., “Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages,”J. Med. Chem.,43:4233-4246, 2000.
Bogdan et al., “Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10,”J. Biol. Chem.,267:23301-23308, 1992.
Clinton et al., “Steroidal[3,2-c]pyrazoles. II. Androstanes, 19-norandrostanes and their unsaturated analogs,”J. Am Chem Soc.,83:1478-1491, 1961.
Dean et al., “Halogenolysis of methyl glycyrrhetate with lithium iodidedimethylformamide,”J. Chem. Soc.,6655-6659, 1965.
Ding et al., “Macrophage deactivating factor and transforming growth factors-beta1, beta2, and beta3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-gamma,”J. Immunol.,940-944, 1990.
Honda et al., “Design and synthesis of 2-cyano-3, 12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages,”Bioorg Med Chem Lett.,8(19):2711-2714, 1998.
Honda et al., “New enone derivatives of oleanolic acid and ursolic acid as inhibitors of nitric oxide production in mouse macrophages,”Bioorg. Med. Chem. Lett.,7:1623-1628, 1997.
Honda et al., “Novel synthetic oleanane triterpenoids: a series of highly active inhibitors of nitric oxide production in mouse macrophages,”Bioorg Med Chem Lett,9(24):3429-3434, 1999.
Johnson et al., “A plan for distinguishing between some five- and six-membered ring ketones,”J. Am Chem. Soc.,67:1745-1754, 1945.
Picard et al., “The triterpene resinols and related acids, part VI,”J. Chem. Soc.,1045-108, 1939.
Sharpless et al., “Electrophilic and nucleophilic organoselenium reagents. New routes to alpha, beta-unsaturated carbonyl compounds,”J. Am. Chem. Soc.,95:6137, 1973.
Simonsen et al., “Tetracyclic hydroxy acids,” Inthe Terpenes, Cambridge University, Cambridge, 5:221-285, 1957.
Suh et al., “A novel synthetic oleanane triterpenoid, 2-cyano-3, 12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity,”Cancer Res., 59(2):336-341, 1999.
Suh et al., “Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages,”Cancer Res., 58:717-723, 1998.
Suh et al., “Novel triterpenoids suppress inducible ntiric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2),” Proceedings of the American Association for Cancer Research Annual Meeting, 39:266, 1998.
Bore et al., “The anti-inflammatory triterpenoid methyl 2-cyano-3, 12-dioxoolean 1,9(11)-dien-28-oate methanol solvate hydrate,” Acta Crystallorg C., 58(Pt 3):o199-o200, 2002.
Favaloro, Jr. et al., “Design and synthesis of tricyclic compounds with enone functionalities in rings A and C: a novel class of highly active inhibitors of nitric oxide production in mouse macrophages,” J Med Chem, 45(22):4801-4805, 2002.
Honda et al., “Efficient synthesis of (−)- and (+)-tricyclic compounds with enome functionalities in rings A and C. A novel class of orally active anti-inflammatory and cancer chemopreventive agents,” Org Biomol Chem, 1:4384-4391, 2003.
Honda et al., “A novel dicyanotriterpenoid, 2-cyano-3, 12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production,” Bioorgainc & Medicinal Chemistry Letters, 12:1027-1030, 2002.
Honda et al., “Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages,” J Med Chem, 43:4233-4246, 2000.
Ikeda et al., “The novel triterpenoid CDDO and its derivatives induce apoptosis by disruption of intracellular redox balance,”Cancer Res., 63:5551-5558, 2003.
Kim et al., “Identification of a novel synthetic triterpenoid, methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate, that potently induces caspace-mediated apoptosis in human lung cancer cells,” Molecular Cancer Therapeutics, 1:177-184, 2002.
Suh et al., “Synthetic triterpenoids enhance transforming growth factor β/Smad signaling,”Cancer Res., 63:1371-1376, 2003.

Affiliated with

Also associated with

Rating

Therapeutic compositions and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic compositions and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic compositions and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3832947